Related Articles
Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: Antagonistic action of a growth-hormone-releasing hormone analog
Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands
Vasoactive intestinal peptide and epidermal growth factor: co-mitogens or inhibitors of keratinocyte proliferation in vitro?
Luteinizing hormone-releasing hormone antagonist Cetrorelix regulates the expression of Gαs and Gαi protein subunits and adenylate cyclase activity in rat ovary, breast and pituitary